Guided Therapeutics annual operating margin
2010
2011
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
Guided Therapeutics's operating margin was −309.26% for fiscal 2025.
View full Guided Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −309.26% | +29805.03 pp |
| 2024 | 2024-12-31 | −30,114.29% | −26586.73 pp |
| 2023 | 2023-12-31 | −3,527.55% | +22110.91 pp |
| 2022 | 2022-12-31 | −25,638.46% | −22722.41 pp |
| 2021 | 2021-12-31 | −2,916.05% | −1884.68 pp |
| 2020 | 2020-12-31 | −1,031.37% | +1571.41 pp |
| 2019 | 2019-12-31 | −2,602.78% | +113.01 pp |
| 2018 | 2018-12-31 | −2,715.79% | −1436.69 pp |
| 2017 | 2017-12-31 | −1,279.10% | +13547.09 pp |
| 2015 | 2015-12-31 | −14,826.19% | −1489.27 pp |
| 2014 | 2014-12-31 | −13,336.92% | −12531.31 pp |
| 2013 | 2013-12-31 | −805.61% | −677.36 pp |
| 2012 | 2012-12-31 | −128.25% | +59.57 pp |
| 2011 | 2011-12-31 | −187.82% | −139.64 pp |
| 2010 | 2010-12-31 | −48.19% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −120.34% | +5862.99 pp |
| Q3 2025 | 2025-09-30 | −808.33% | +710.42 pp |
| Q2 2025 | 2025-06-30 | −652.14% | +2768.32 pp |
| Q4 2024 | 2024-12-31 | −53,300.00% | −49468.18 pp |
| Q1 2024 | 2024-03-31 | −5,983.33% | +34816.67 pp |
| Q4 2023 | 2023-12-31 | −1,518.75% | +12821.25 pp |
| Q2 2023 | 2023-06-30 | −3,420.45% | +5439.55 pp |
| Q1 2023 | 2023-03-31 | −3,831.82% | −3013.48 pp |
| Q3 2022 | 2022-09-30 | −40,800.00% | −38236.84 pp |
| Q2 2022 | 2022-06-30 | −14,340.00% | +13710.00 pp |
| Q1 2022 | 2022-03-31 | −8,860.00% | −7708.00 pp |
| Q4 2021 | 2021-12-31 | −818.33% | −619.63 pp |
| Q3 2021 | 2021-09-30 | −2,563.16% | −1531.91 pp |
| Q2 2021 | 2021-06-30 | −28,050.00% | −9250.00 pp |
| Q4 2020 | 2020-12-31 | −1,152.00% | +31548.00 pp |
| Q3 2020 | 2020-09-30 | −198.70% | +1229.08 pp |
| Q4 2019 | 2019-12-31 | −1,031.25% | +8.28 pp |
| Q3 2019 | 2019-09-30 | −18,800.00% | −7100.00 pp |
| Q2 2019 | 2019-06-30 | −32,700.00% | −26562.50 pp |
| Q1 2019 | 2019-03-31 | −1,427.78% | +7972.22 pp |
| Q4 2018 | 2018-12-31 | −1,039.53% | −325.94 pp |
| Q3 2018 | 2018-09-30 | −11,700.00% | −7642.42 pp |
| Q2 2018 | 2018-06-30 | −6,137.50% | −5524.86 pp |
| Q1 2018 | 2018-03-31 | −9,400.00% | −6952.38 pp |
| Q4 2017 | 2017-12-31 | −713.59% | +1.14 pp |
| Q3 2017 | 2017-09-30 | −4,057.58% | +10386.87 pp |
| Q2 2017 | 2017-06-30 | −612.64% | +22362.36 pp |
| Q1 2017 | 2017-03-31 | −2,447.62% | +13562.38 pp |
| Q3 2016 | 2016-09-30 | −714.74% | +9205.26 pp |
| Q4 2015 | 2015-12-31 | −14,444.44% | +2078.63 pp |
| Q3 2015 | 2015-09-30 | −22,975.00% | −11997.73 pp |
| Q2 2015 | 2015-06-30 | −16,010.00% | +2417.27 pp |
| Q1 2015 | 2015-03-31 | −9,920.00% | +1022.11 pp |
| Q4 2014 | 2014-12-31 | −16,523.08% | −16131.77 pp |
| Q3 2014 | 2014-09-30 | −10,977.27% | −9070.30 pp |
| Q2 2014 | 2014-06-30 | −18,427.27% | −17643.04 pp |
| Q1 2014 | 2014-03-31 | −10,942.11% | −9819.35 pp |
| Q4 2013 | 2013-12-31 | −391.30% | −275.99 pp |
| Q3 2013 | 2013-09-30 | −1,906.98% | −1767.01 pp |
| Q2 2013 | 2013-06-30 | −784.23% | −658.77 pp |
| Q1 2013 | 2013-03-31 | −1,122.75% | −984.04 pp |
| Q4 2012 | 2012-12-31 | −115.32% | +206.34 pp |
| Q3 2012 | 2012-09-30 | −139.97% | +119.48 pp |
| Q2 2012 | 2012-06-30 | −125.46% | −72.34 pp |
| Q1 2012 | 2012-03-31 | −138.72% | −42.24 pp |
| Q4 2011 | 2011-12-31 | −321.65% | −255.69 pp |
| Q3 2011 | 2011-09-30 | −259.45% | — |
| Q2 2011 | 2011-06-30 | −53.12% | — |
| Q1 2011 | 2011-03-31 | −96.48% | — |
| Q2 2010 | 2010-06-30 | −65.96% | — |
Over the last five reported fiscal years, Guided Therapeutics's operating margin increased from −1,031.37% to −309.26%, a change of +722.12 percentage points. The latest reported quarter, Q4 2025, shows −120.34%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Guided Therapeutics filings at SEC.gov ↗